Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Adamis receives European patent for novel cell-based cancer vaccine technology

Adamis Pharmaceuticals Corporation, today announced the technology which constitutes the basis of a novel cell-based cancer vaccine, TeloB-VAX, was recently granted a patent in Europe.

14 Jul 2011

Scientists identify DNA variants linked with elevated risk of prostate cancer

Doctors have known for a long time that prostate cancer "runs in the family". Men with relatives who have been diagnosed with prostate cancer have an elevated risk of also developing this type of cancer. It was only last year that DKFZ scientists calculated that this risk rises with the number of affected direct family members and also depends on the relatives' age at outbreak of the disease.

13 Jul 2011

Victorian Minister for Health and Carlton Football Club encourage men to check for prostate cancer

The Victorian Government has joined forces with The Pratt Foundation and Carlton Football Club to launch the Richard Pratt Fellowships in Prostate Cancer Research.

13 Jul 2011

Scientists discover seven new gene variants that increase risk of prostate cancer

Cancer Research UK-funded scientists have taken a further step to identifying men at a greater risk of prostate cancer with the discovery of seven new variants in the human genome that increase the chances of developing the disease.

11 Jul 2011

Medicare coverage, pricey cancer drugs and the 'rationing' issue

As health care costs play an ever-increasing role in Washington's budget drama, Medicare officials announced last week they will continue to pay for two extremely expensive cancer treatments despite lingering questions about their effectiveness. At a cost of about $88,000 per year, the cancer-fighting Avastin will still be available to eligible senior citizens for breast cancer treatment.

7 Jul 2011

Eighteen scientists receive Damon Runyon Cancer Research Foundation awards

The Damon Runyon Cancer Research Foundation, a non-profit organization focused on supporting innovative early career researchers, named 18 new Damon Runyon Fellows at its spring Fellowship Award Committee review.

7 Jul 2011

New insight into tumor biology

Cancer cells are well known for their altered metabolisms, which may help them generate the energy they need for rapid growth. Using an emerging imaging technology, researchers reporting in the July Cell Metabolism, a Cell Press publication, have discovered that those metabolic shifts actually develop even before detectable tumors form.

6 Jul 2011

Medicare to cover 2 expensive cancer drugs

Medicare confirmed on Thursday that it would continue to pay for two expensive cancer drugs that had been at the center of debate — Avastin from Genentech for breast cancer and Provenge from Dendreon for prostate cancer.

2 Jul 2011

First Edition: July 1, 2011

Today's early morning highlights from the major news organizations, including reports about sleep deprived medical residents, decisions by Medicare officials on covering two expensive drugs and states struggling with budget cuts.

1 Jul 2011

FDA grants Advaxis pre-IND meeting for Advaxis-PSA immunotherapy for prostate cancer

Advaxis, Inc.,, a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has been granted a pre-Investigational New Drug meeting with the U.S. Food and Drug Administration on August 10, 2011 to discuss the CMC, pharmacology, toxicology, and clinical plans for Advaxis PSA, its construct to fight prostate cancer.

1 Jul 2011

Sensitivity of bladder cancer cells linked to chemotherapy and expression of miR-34a gene

Researchers at the UC Davis Cancer Center have discovered a way of sensitizing muscle-invasive bladder cancer cells so that they succumb to the toxic effects of chemotherapy. The finding adds to mounting evidence that tiny strands of RNA - called microRNA - play key roles in some of the deadliest types of cancer.

30 Jun 2011

Dendreon receives FDA approval for Los Angeles cancer immunotherapy manufacturing facility

Dendreon Corporation today announced that the U.S. Food and Drug Administration approved its Los Angeles cancer immunotherapy manufacturing facility, allowing the company to continue to increase the availability of PROVENGE across the U.S. to help meet the needs of patients with asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer.

30 Jun 2011

GenSpera and University of Copenhagen collaborate on 'Sustainable Production of Thapsigargin using Light'

GenSpera, Inc. has entered into a cooperation agreement with the University of Copenhagen, in Copenhagen, Denmark, to collaborate on the "SPOTLight" (Sustainable Production of Thapsigargin using Light) project.

29 Jun 2011

DiagnoCure, Signal Genetics enter commercialization collaboration for Previstage GCC Colorectal Cancer Staging Test

Signal Genetics, a privately held predictive genetic testing company focusing on oncology, and DiagnoCure, Inc., a life sciences company that develops and commercializes high-value cancer diagnostic tests, today announced a collaboration arrangement valued at US$13.3M over the first five years.

29 Jun 2011

New prostate cancer drugs bring cost of care into spotlight

Meanwhile, results from a three-decade Swedish study found that women who have mammograms have a lower death rate from breast cancer — a finding that some say may ease recent controversies around the screening procedure.

29 Jun 2011

First Edition: June 28, 2011

Today's headlines include reports from the states about action on public employee benefit reforms and Planned Parenthood funding.

28 Jun 2011

Amgen files sBLA for XGEVA with FDA to treat castrate-resistant prostate cancer

Amgen today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) to expand the indication for XGEVA (denosumab) to treat men with castrate-resistant prostate cancer to reduce the risk of developing bone metastases.

28 Jun 2011

Prostate cancer therapy may benefit patients with oestrogen-negative breast cancer

CANCER RESEARCH UK Cancer Research UK scientists have discovered why a sub group of oestrogen-receptor-negative breast cancer patients could benefit from prostate cancer treatments which target the cell's androgen receptor - a key driver of prostate cancer, according to research published in The EMBO Journal today.

27 Jun 2011

Health Canada grants market authorization for Sanofi-aventis Jevtana to treat prostate cancer

Sanofi-aventis announced today that Health Canada has granted market authorization for Jevtana injection in combination with prednisone for the treatment of patients with metastatic castration resistant prostate cancer, previously treated with a docetaxel-containing treatment regimen.

24 Jun 2011

Homosexual men with prostate cancer more likely to report problems with bicalutamide drug

Homosexual men taking bicalutamide for prostate cancer were much more likely to report sexual problems during treatment than heterosexual patients, according to a study in the July issue of the urology journal BJUI.

22 Jun 2011

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Adamis receives European patent for novel cell-based cancer vaccine technology

Scientists identify DNA variants linked with elevated risk of prostate cancer

Victorian Minister for Health and Carlton Football Club encourage men to check for prostate cancer

Scientists discover seven new gene variants that increase risk of prostate cancer

Medicare coverage, pricey cancer drugs and the 'rationing' issue

Eighteen scientists receive Damon Runyon Cancer Research Foundation awards

New insight into tumor biology

Medicare to cover 2 expensive cancer drugs

First Edition: July 1, 2011

FDA grants Advaxis pre-IND meeting for Advaxis-PSA immunotherapy for prostate cancer

Sensitivity of bladder cancer cells linked to chemotherapy and expression of miR-34a gene

Dendreon receives FDA approval for Los Angeles cancer immunotherapy manufacturing facility

GenSpera and University of Copenhagen collaborate on 'Sustainable Production of Thapsigargin using Light'

DiagnoCure, Signal Genetics enter commercialization collaboration for Previstage GCC Colorectal Cancer Staging Test

New prostate cancer drugs bring cost of care into spotlight

First Edition: June 28, 2011

Amgen files sBLA for XGEVA with FDA to treat castrate-resistant prostate cancer

Prostate cancer therapy may benefit patients with oestrogen-negative breast cancer

Health Canada grants market authorization for Sanofi-aventis Jevtana to treat prostate cancer

Homosexual men with prostate cancer more likely to report problems with bicalutamide drug

What to know about prostate cancer eBook

Transforming Lab Workflows with Cell Culture Automation

Building Bridges to Scalable Allogeneic Cell Therapy

Edoardo Fabini

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

What to know about prostate cancer eBook

Transforming Lab Workflows with Cell Culture Automation

Building Bridges to Scalable Allogeneic Cell Therapy

Edoardo Fabini

Newsletters you may be interested in